12 min read | Unique research highlights an overlooked mental health disparity among Indigenous North American people with HD – and the need for care grounded in trust, community partnership, and ...

HDBuzz has been following SKY-0515 since the first results from its Phase 1 study were announced in 2024. Early testing in ...

First to speak was Aikaterini Papadopoulou, who talked about her work targeting a fragment of the expanded HTTHTT one abbreviation for the gene that causes Huntington’s disease. The same gene is also ...

⏱️10 min read | Results from the VIBRANT-HD trial are now published in a peer reviewed journal. This trial tested the oral drug, branaplam, which lowered HTT but had serious safety problems, ...

A new collaboration between researchers at Indiana University Southeast and Bellarmine University in Kentucky, both in the USA, aimed to investigate what happens when a physical therapist and a music ...

Skyhawk Therapeuticstherapeutics treatments has announced results from a Phase 1 clinical study of its experimental huntingtin-lowering drug, SKY-0515. As with all Phase 1 studies, the main goal was ...

Long-time HDBuzz readers may recognise pridopidine. Pridopidine has had one of the longest and most winding development journeys of any experimental HD therapy. Originally developed as a treatment for ...

In plain language. Written by scientists. We're proud to announce Molly Gracey as a 2024 HDBuzz Prize winner! Could social skills be the secret ingredient to a better quality of life in people with ...

In plain language. Written by scientists. A gene called MSH3 helps to repair our DNA, but in HD it can slip up and cause CAG repeats to lengthen. Researchers have uncovered new information about how ...

In plain language. Written by scientists. Roche gave an update this week about GENERATION HD2, testing the HTT-lowering drug tominersen in people with HD. The trial is continuing, but only the higher ...

People who develop Huntington’s disease (HD) are born with the genetic change that causes the disease. So why does it take decades, usually around 40 to 50 years, for the symptoms of the disease to ...

This week, we heard an update from Roche about their huntingtin-lowering therapy, tominersen, currently being tested in the GENERATION HD2 trial. An independent data monitoring committeemonitoring ...